enGene Therapeutics (ENGN) Prepaid Assets (2022 - 2026)
enGene Therapeutics (ENGN) posted quarterly Prepaid Assets of $10.6 million for Q2 2026, up 6.63% year-over-year from $10.0 million in Q2 2025, and down 11.33% quarter-over-quarter from $12.0 million in Q1 2026.
enGene Therapeutics (ENGN) Prepaid Assets (2022 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Prepaid Assets for 5 consecutive years, with $10.6 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Prepaid Assets rose 6.63% year-over-year to $10.6 million; the TTM figure through Apr 2026 stood at $10.6 million (up 6.63% YoY), while the FY2025 annual figure was $6.6 million, down 22.92% from the prior year.
- Prepaid Assets slipped to $10.6 million in Q2 2026 per ENGN's latest filing, from $12.0 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $12.0 million in Q1 2026 and bottomed at $739000.0 in Q4 2022.
- Historically, Prepaid Assets has averaged $6.5 million across 5 years, with a median of $7.3 million in 2025.
- Annual changes were most pronounced in 2024 — Prepaid Assets soared 475.07% — and 2025, when it retreated 22.92%.
- enGene Therapeutics' Prepaid Assets stood at $739000.0 in 2022, then soared by 102.98% to $1.5 million in 2023, then jumped by 475.07% to $8.6 million in 2024, then decreased by 22.92% to $6.6 million in 2025, then jumped by 59.99% to $10.6 million in 2026.
- Business Quant data shows ENGN's Prepaid Assets at $10.6 million in Q2 2026, $12.0 million in Q1 2026, and $6.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 10.64 Mn |
| Jan 31, 2026 | 12.00 Mn |
| Oct 31, 2025 | 6.65 Mn |
| Jul 31, 2025 | 8.62 Mn |
| Apr 30, 2025 | 9.98 Mn |
| Jan 31, 2025 | 8.00 Mn |
| Oct 31, 2024 | 8.63 Mn |
| Jul 31, 2024 | 4.70 Mn |
| Apr 30, 2024 | 3.51 Mn |
| Jan 31, 2024 | 2.72 Mn |
| Oct 31, 2023 | 1.50 Mn |
| Oct 31, 2022 | 739,000.00 |